Cytarabine and daunorubicin for the treatment of acute myeloid leukemia
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cytarabine and daunorubicin for the treatment of acute myeloid leukemia
Authors
Keywords
-
Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 18, Issue 16, Pages 1765-1780
Publisher
Informa UK Limited
Online
2017-10-11
DOI
10.1080/14656566.2017.1391216
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MDS with deletions in the long arm of chromosome 11 are associated with a high frequency of SF3B1 mutations
- (2017) A Stengel et al. LEUKEMIA
- Precision oncology for acute myeloid leukemia using a knowledge bank approach
- (2017) Moritz Gerstung et al. NATURE GENETICS
- Income and Cancer Overdiagnosis — When Too Much Care Is Harmful
- (2017) H. Gilbert Welch et al. NEW ENGLAND JOURNAL OF MEDICINE
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
- (2017) Richard M. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia
- (2016) A. K. Burnett et al. BLOOD
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups
- (2016) M. R. Luskin et al. BLOOD
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- Role of drug transport and metabolism in the chemoresistance of acute myeloid leukemia
- (2016) Jose J.G. Marin et al. BLOOD REVIEWS
- TP53mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation
- (2016) Jan M. Middeke et al. BRITISH JOURNAL OF HAEMATOLOGY
- Population pharmacokinetics of Daunorubicin in adult patients with acute myeloid leukemia
- (2016) Savitha Varatharajan et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Genetic and epigenetic heterogeneity in acute myeloid leukemia
- (2016) Sheng Li et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications
- (2016) Ling Zhang et al. LEUKEMIA & LYMPHOMA
- Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia
- (2016) Stefanie Göllner et al. NATURE MEDICINE
- DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling
- (2016) Olga A Guryanova et al. NATURE MEDICINE
- Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia
- (2016) Sheng Li et al. NATURE MEDICINE
- TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
- (2016) John S. Welch et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic Classification and Prognosis in Acute Myeloid Leukemia
- (2016) Elli Papaemmanuil et al. NEW ENGLAND JOURNAL OF MEDICINE
- A randomized comparison of daunorubicin 90 mg/m 2 vs 60 mg/m 2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients
- (2015) Alan K. Burnett et al. BLOOD
- Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: A SEER database analysis
- (2015) Mary-Elizabeth M. Percival et al. CANCER
- Mutational Cooperativity Linked to Combinatorial Epigenetic Gain of Function in Acute Myeloid Leukemia
- (2015) Alan H. Shih et al. CANCER CELL
- Chemotherapy options for previously untreated acute myeloid leukemia
- (2015) Ryan C Lynch et al. EXPERT OPINION ON PHARMACOTHERAPY
- Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia
- (2015) J. F. Zeidner et al. HAEMATOLOGICA
- Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia
- (2015) Jeffery M. Klco et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Phase III Open-Label Randomized Study of Cytarabine in Combination With Amonafide L-Malate or Daunorubicin As Induction Therapy for Patients With Secondary Acute Myeloid Leukemia
- (2015) Richard M. Stone et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
- (2015) Christoph Röllig et al. LANCET ONCOLOGY
- Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia
- (2015) R B Walter et al. LEUKEMIA
- Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the study alliance leukemia
- (2015) C Müller-Tidow et al. LEUKEMIA
- RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia
- (2015) Ajay Abraham et al. PHARMACOGENOMICS
- TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution
- (2015) H-A Hou et al. Blood Cancer Journal
- Role of Microenvironment in Resistance to Therapy in AML
- (2015) Yoko Tabe et al. Current Hematologic Malignancy Reports
- Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia
- (2015) J. F. Zeidner et al. HAEMATOLOGICA
- Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML
- (2014) J. E. Lancet et al. BLOOD
- Acute myeloid leukemia ontogeny is defined by distinct somatic mutations
- (2014) R. C. Lindsley et al. BLOOD
- Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML
- (2014) Jorge E. Cortes et al. CANCER
- Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
- (2014) Robert K Hills et al. LANCET ONCOLOGY
- Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia
- (2014) Liran I. Shlush et al. NATURE
- Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia
- (2014) Terrence N. Wong et al. NATURE
- Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission
- (2014) M. R. Corces-Zimmerman et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
- (2013) S. H. Petersdorf et al. BLOOD
- Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis
- (2013) Oliver Teuffel et al. BRITISH JOURNAL OF HAEMATOLOGY
- Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial
- (2013) Hubert Serve et al. JOURNAL OF CLINICAL ONCOLOGY
- High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial
- (2013) Roelof Willemze et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term results of a randomized phase 3 trial comparing idarubicin and daunorubicin in younger patients with acute myeloid leukaemia
- (2013) C Récher et al. LEUKEMIA
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Reprise: Gemtuzumab Ozogamicin for Older Patients With Acute Myeloid Leukemia
- (2012) Donna S. Neuberg JOURNAL OF CLINICAL ONCOLOGY
- Cladribine, But Not Fludarabine, Added to Daunorubicin and Cytarabine During Induction Prolongs Survival of Patients With Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Study
- (2012) Jerzy Holowiecki et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia
- (2012) Alan K. Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
- (2012) Sylvie Castaigne et al. LANCET
- Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia
- (2012) E.J. Feldman et al. LEUKEMIA RESEARCH
- Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
- (2012) Jay P. Patel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients
- (2011) U. Brunnberg et al. ANNALS OF ONCOLOGY
- A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia
- (2011) J.-H. Lee et al. BLOOD
- TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome
- (2011) F. G. Rucker et al. BLOOD
- TET2Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
- (2011) Klaus H. Metzeler et al. JOURNAL OF CLINICAL ONCOLOGY
- First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
- (2011) Eric J. Feldman et al. JOURNAL OF CLINICAL ONCOLOGY
- Cytarabine Dose for Acute Myeloid Leukemia
- (2011) Bob Löwenberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study
- (2010) S. Ohtake et al. BLOOD
- Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999
- (2010) L. D. Cripe et al. BLOOD
- Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
- (2010) D. Grimwade et al. BLOOD
- Randomized Study of Intensified Anthracycline Doses for Induction and Recombinant Interleukin-2 for Maintenance in Patients With Acute Myeloid Leukemia Age 50 to 70 Years: Results of the ALFA-9801 Study
- (2010) Cecile Pautas et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial
- (2010) Alan K. Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- DNMT3AMutations in Acute Myeloid Leukemia
- (2010) Timothy J. Ley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
- (2009) O. Abdel-Wahab et al. BLOOD
- Daunorubicin Versus Mitoxantrone Versus Idarubicin As Induction and Consolidation Chemotherapy for Adults With Acute Myeloid Leukemia: The EORTC and GIMEMA Groups Study AML-10
- (2009) Franco Mandelli et al. JOURNAL OF CLINICAL ONCOLOGY
- Anthracycline Dose Intensification in Acute Myeloid Leukemia
- (2009) Hugo F. Fernandez et al. NEW ENGLAND JOURNAL OF MEDICINE
- High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
- (2009) Bob Löwenberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutation inTET2in Myeloid Cancers
- (2009) François Delhommeau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genetic factors influencing cytarabine therapy
- (2009) Jatinder K Lamba PHARMACOGENOMICS
- Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry
- (2008) G. Juliusson et al. BLOOD
- Liposomal daunorubicinversusstandard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia
- (2008) Roberto Latagliata et al. BRITISH JOURNAL OF HAEMATOLOGY
- TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype and is associated with very poor prognosis
- (2008) D Bowen et al. LEUKEMIA
- In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy
- (2008) Paul Tardi et al. LEUKEMIA RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More